Targeted therapy in non-small cell lung cancer

[1] Targetingepidermalgrowthfactorreceptor arewemissingthemark?. DanceyJE,FreidlinB. The Lancet . 2003

[2] Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase Ⅲ trial-INTACT 1. Giaccone G, Herbst RS, Manegold C, et al. Journal of Clinical Oncology . 2004

[3] AphaseⅡtrailoftheepidermalgrowthfactor(EGFR)tyrosinekinasein hibitorOSI 774,followingplatinum basedchemotherapy,inpa tientswithadvancedEGFR expressingnon smallcelllungcancer(NSCLC). PerezSolerR,ChachouaA,HubermanM ,etal. Proceedings of the American Society of Clinical Oncology . 2001

[4] ZD1839ismoreeffectiveinpa tients (pts)withnon smallcelllungcancer (NSCLC)whowerelife timenon tobaccousers. WongNS,LimST,LimWT ,etal. Proceedings of the American Society of Clinical Oncology . 2003

[5] Antiangiogenic hypoxic cytotoxin TX-402 inhibits hypoxia-inducible factor 1 signaling pathway. Nagasawa H,Mikamo N,Nakajima Y, et al. Anticancer Research . 2003

[6] ProteasomeinhibitionwithPS 341 (bortezomib)inlungcancertherapy. LaraPNJr,DaviesAM,MackPC ,etal. Seminars in Oncology . 2004

[7] Epidermalgrowth factor family of receptors in preneoplasia and lungcancer:perspectives for targeted therapies. Hirsch FR,Scagliotti GV,Langer CJ,et al. Lung Cancer . 2003

[8] Targeting angiogenesis:A review ofangiogenesis inhibitors in the treatment of lung cancer. Sridhar SS,Shepherd FA. Lung Cancer . 2003

[9] Antisense BAG-1sensitizes He-La cells to apoptosis by multiple pathways. Xiong J,ChenJ,Chemenko G,et al. Biochemical and Biophysical Research Communications . 2003

[10] Antitumor activity of ZD6474,a vascular endothelial growth factor receptor tyrosine kinase inhibitor,in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy. Ciardiello F, Bianco R, Caputo R, et al. Clinical Cancer Research . 2004

[1] Targetingepidermalgrowthfactorreceptor arewemissingthemark?. DanceyJE,FreidlinB. The Lancet . 2003

[2] Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase Ⅲ trial-INTACT 1. Giaccone G, Herbst RS, Manegold C, et al. Journal of Clinical Oncology . 2004

[3] AphaseⅡtrailoftheepidermalgrowthfactor(EGFR)tyrosinekinasein hibitorOSI 774,followingplatinum basedchemotherapy,inpa tientswithadvancedEGFR expressingnon smallcelllungcancer(NSCLC). PerezSolerR,ChachouaA,HubermanM ,etal. Proceedings of the American Society of Clinical Oncology . 2001

[4] ZD1839ismoreeffectiveinpa tients (pts)withnon smallcelllungcancer (NSCLC)whowerelife timenon tobaccousers. WongNS,LimST,LimWT ,etal. Proceedings of the American Society of Clinical Oncology . 2003

[5] Antiangiogenic hypoxic cytotoxin TX-402 inhibits hypoxia-inducible factor 1 signaling pathway. Nagasawa H,Mikamo N,Nakajima Y, et al. Anticancer Research . 2003

[6] ProteasomeinhibitionwithPS 341 (bortezomib)inlungcancertherapy. LaraPNJr,DaviesAM,MackPC ,etal. Seminars in Oncology . 2004

[7] Epidermalgrowth factor family of receptors in preneoplasia and lungcancer:perspectives for targeted therapies. Hirsch FR,Scagliotti GV,Langer CJ,et al. Lung Cancer . 2003

[8] Targeting angiogenesis:A review ofangiogenesis inhibitors in the treatment of lung cancer. Sridhar SS,Shepherd FA. Lung Cancer . 2003

[9] Antisense BAG-1sensitizes He-La cells to apoptosis by multiple pathways. Xiong J,ChenJ,Chemenko G,et al. Biochemical and Biophysical Research Communications . 2003

[10] Antitumor activity of ZD6474,a vascular endothelial growth factor receptor tyrosine kinase inhibitor,in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy. Ciardiello F, Bianco R, Caputo R, et al. Clinical Cancer Research . 2004